Synopsis: Jefferies expects hospital operators to post double-digit revenue growth this quarter on strong patient demand, though expansion costs may weigh on margins. One operator is expected to outperform the rest.
India’s hospital operators are set to post another quarter of healthy growth, according to brokerage firm Jefferies, even as near-term profitability takes a hit from ongoing expansion activity. Patient volumes across the sector remain strong, but the cost of commissioning new facilities is expected to keep margins in check for most players. Here is how the four major hospital names are expected to perform this quarter.
Apollo Hospitals
Apollo Hospitals is expected to remain the best performer in Jefferies’ hospital coverage this quarter. The brokerage sees the core hospital business growing in the high teens year-on-year, a pace that continues to outstrip much of its peer group.
Beyond the hospital segment, Jefferies is also watching HealthCo, the company’s digital health and pharmacy arm, where profitability has been steadily improving. This improvement is expected to help cushion the impact of the company’s continued investments across its network, ultimately supporting overall earnings growth for the quarter.
Global Health (Medanta)
Global Health, which runs hospitals under the Medanta brand, is expected to post double-digit revenue growth for the quarter. Jefferies attributes this to healthy patient demand across its facilities.
That said, the brokerage flags that margins could come under some pressure, largely on account of costs tied to the company’s newer hospital projects, which typically take time to reach optimal occupancy and profitability.
Fortis Healthcare
Fortis Healthcare is also expected to deliver double-digit revenue growth, backed by what Jefferies describes as robust demand across its hospital network. However, similar to its peers, the brokerage expects costs linked to commissioning new facilities to weigh on margins in the near term.
This is a fairly common pattern across the sector right now, where topline growth is strong but the expansion phase keeps profitability metrics from fully catching up.
Max Healthcare
Rounding out the list, Max Healthcare is projected to post double-digit revenue growth as well, with Jefferies pointing to strong occupancy levels and healthy patient volumes as the key drivers. Even so, the brokerage expects expansion-related expenses to keep margin expansion somewhat subdued for now, suggesting that the benefits of the company’s growing bed capacity may take a few more quarters to fully show up in profitability.
Overall, Jefferies’ outlook for the hospital sector reflects a familiar theme this earnings season: demand is not the problem. Every major operator in this list is expected to post double-digit or better revenue growth, driven by consistently strong patient volumes and occupancy across facilities.
The real story lies in margins, where the sector’s aggressive expansion push is creating a temporary drag on profitability. New hospitals typically need time to ramp up occupancy and operational efficiency, and until that happens, the costs of commissioning and running these facilities tend to eat into near-term earnings.
Apollo Hospitals stands out as the exception here, with Jefferies expecting it to outpace the rest of the pack, helped along by the improving performance of its HealthCo business, which appears to be offsetting some of the drag from expansion elsewhere in the company.
For Global Health, Fortis, and Max Healthcare, the quarter looks set to be more about proving out demand strength while investors wait for expansion costs to ease and newer facilities to mature. If patient volumes hold up as expected, the current phase of margin pressure may well turn into a tailwind for these companies once their newer hospitals move past the early ramp-up stage.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
